Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $243.53 +1.16%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 5 | New: 25
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 5 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $283.00 (from $280.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Teradata (TDC) PT Lowered to $32 at UBS on Cautious Q3 View
- Brinker Int'l (EAT) PT Lowered to $210 at DA Davidson as Same Store Sales Expected to Normalize
- Shift4 Payments (FOUR) PT Lowered to $56 at StoneX as Iran War Impacts Revenues
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
